Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil

Am J Hematol. 2018 Jul;93(7):E175-E177. doi: 10.1002/ajh.25119. Epub 2018 May 6.

Authors

Maurizio Miano¹, Gioacchino Andrea Rotulo¹, Elena Palmisani¹, Mariateresa Giaimo¹, Francesca Fioredda¹, Filomena Pierri¹, Agnese Pezzulla², Maria Licciardello², Paola Terranova¹, Tiziana Lanza¹, Enrico Cappelli¹, Rosario Maggiore¹, Michaela Calvillo¹, Concetta Micalizzi¹, Giovanna Russo², Carlo Dufour¹

Affiliations

¹ Hematology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
² Haematology/Oncology Unit, Dept of Pediatrics, University of Catania- Catania, Italy.

PMID: 29675829
DOI: 10.1002/ajh.25119

No abstract available

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Infant
Male
Mycophenolic Acid / pharmacology
Mycophenolic Acid / therapeutic use
Purpura, Thrombocytopenic, Idiopathic / therapy*
Retrospective Studies
Salvage Therapy / methods*
Sirolimus / therapeutic use*
TOR Serine-Threonine Kinases / antagonists & inhibitors
Treatment Outcome
Young Adult

Substances

MTOR protein, human
TOR Serine-Threonine Kinases
Mycophenolic Acid
Sirolimus